Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery.
The efficacy of 1.0% apraclonidine (para-aminoclonidine) in preventing the rise of intraocular pressure following anterior segment, laser surgery was evaluated in a randomised double-masked study. Ninety-nine consecutive patients requiring laser treatment of the anterior segment were included in the study. They were randomised into two groups, one receiving 1.0% para-aminoclonidine and the other placebo (vehicle of para-aminoclonidine). The drug caused a statistically significant reduction in pressure after the laser treatment without causing clinically significant side effects such as bradycardia or hypotension.
Sridharrao
B
B
Vision Research Foundation, Madras, India.
Badrinath
S S
SS
D000328:Adult; D000368:Aged; D000869:Anterior Eye Segment / Q000601:surgery*; D001794:Blood Pressure / Q000187:drug effects; D003000:Clonidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D053685:Laser Therapy / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
C016986:apraclonidine; D003000:Clonidine